Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2026)

Catalyst Pharmaceuticals has reported Deferred Taxes for 7 years, with the latest figure at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 0.65% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 31.11% YoY), and the FY2025 full-year result was $6.8 million, down 27.05% from the prior year.
• Deferred Taxes for Q1 2026 stood at $2.3 million, down from $4.5 million in the prior quarter.
• The five-year high for Deferred Taxes was $13.9 million in Q3 2023, with the low at -$2.6 million in Q4 2024.
• Historically, Deferred Taxes has averaged $1.9 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2023 — Deferred Taxes soared 1592.83% — and 2024, when it sank 189.35%.
• Catalyst Pharmaceuticals' Deferred Taxes stood at -$1.3 million in 2022, then surged by 31.28% to -$883000.0 in 2023, then slumped by 189.35% to -$2.6 million in 2024, then jumped by 276.56% to $4.5 million in 2025, then slumped by 48.22% to $2.3 million in 2026.
• The last three Deferred Taxes figures came in at $2.3 million (Q1 2026), $4.5 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.